TROG Cancer Research
Members Login   CQMS Login

TROG 15.03 FASTRACK II

Primary sponsor: Trans Tasman Radiation Oncology Group (TROG)

Title

Focal Ablative Stereotactic Radiosurgery for Cancers of the Kidney - a Phase II Clinical Trial

Summary

Surgery is the standard treatment for primary kidney cancer, however, in some cases surgery is either not possible or other health problems make surgery high risk. This study involves a relatively new, highly precise multidirectional radiotherapy technique called Stereotactic Ablative Body Radiotherapy (SABR) and all participants will receive this radiotherapy technique. The aim of the study is to test the ability of this technique to control the cancer within the kidney for those people where surgery is not an option, as well as to examine the side effects of the treatment, including how it may affect your kidney’s function.

Participating centres

Current participating centres (PDF)

Accrual target

70

Current accrual

Current accrual graph (PDF)

Expected date of accrual completion

September 2021

Trial chairperson

A/Prof Shankar Siva, Peter MacCallum Cancer Centre, VIC

Trial contact

Courtney Hill 
TROG Trial Coordinating Centre
Phone: +61 2 401 43900
Email: FASTRACKII@trog.com.au

Further information

TROG trial 15.03 on Australian Cancer Trials website

Trial resources for TROG members

TROG 15.03 member page

We are thankful to our 14,500 patients who have participated in our research. Please continue the generous support.